These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 21903737)

  • 1. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
    Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
    COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
    Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
    Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F; Milot J
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
    Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
    Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
    Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E
    Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
    Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
    Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
    Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclidinium bromide for stable chronic obstructive pulmonary disease.
    Ni H; Soe Z; Moe S
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.
    Jones PW; Leidy NK; Hareendran A; Lamarca R; Chuecos F; Garcia Gil E
    Respir Res; 2016 May; 17(1):61. PubMed ID: 27215749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
    Gelb AF; Tashkin DP; Make BJ; Zhong X; Garcia Gil E; Caracta C;
    Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
    Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
    Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
    Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
    Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
    Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.